Redeye provides its initial take on Surgical Science’s Q4 2023 report, which broadly underperformed ...
Net sales SEK 190m, -3% vs ABGSCe, +3% vs Factset cons.
Redeye states that while the Q4 report was in line with expectations, ad prices remains muted and wi...
Advenica delivered a solid 2023 with a 25% increase in sales, primarily driven by substantial gains...
Redeye comments on the FDA approval to start a randomized phase IIb study with nadunolimab in pancre...
Redeye saw a sales development that was better than our expectations.
Redeye updates its estimates and valuation following Freemelt’s Q4 report, which exceeded expectatio...
The short-term outlook for Enersense looks reasonably good.
Adj. EBITA of SEK 63m, 0% vs. ABGSCe in Q4 FCF was softer because of negative working capital effect...
Good ending to 2023 with strong margin improvements We lift '24e-'25e EBIT by 9-5% on lower opex Sha...
We cut '24e-'25e adj. EBIT by 17-13% Aurdel and EFUEL likely to delay recovery '24e-'25e EV/EBIT 37x...
AcuCort har publicerat bolagets delårsrapport för det fjärde kvartalet 2023.
Spelbolaget Starbreeze rapporterade en nettoomsättning som var en bit under Analysguidens prognos.
Topline i linje med våra årsestimat Nettoomsättningen under Q4’2023 uppgick till 16 mkr (17) och rör...
Inga överraskningar – fortsatt låg kostnadsbas att vänta OncoZenges rapport för det fjärde kvartalet...
Q4’2023 Karolinska Development redovisade ett totalt verkligt värde om 1 440 mkr och ett netto verkl...
Redeye provides a short comment on this morning’s Q4 report from Ortoma.
Redeye saw sales that were above and results that were below our expectations.
Sales +110%, adj. EBIT SEK -0.5m vs. ABGSCe Some more revenue recognised in this quarter, order book...
Redeye leaves a comment following the recent announcement by Faron stating that the company is in se...
